Indication
As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
Medicine details
- Medicine name:
- loncastuximab tesirine (Zynlonta)
- SMC ID:
- SMC2609
- Pharmaceutical company
- Swedish Orphan
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 February 2024
- SMC meeting date:
- 09 January 2024
- Patient group submission deadline:
- 06 November 2023